Is Symbiox Investme overvalued or undervalued?

As of 5 September 2025, the valuation grade for Symbiox Investme has moved from fair to attractive, indicating a more favorable outlook for the company. Based on the analysis, Symbiox Investme appears to be undervalued. The company has a PE ratio of 8.60, a price to book value of 0.27, and a PEG ratio of 0.05, which are significantly lower than many of its peers. For instance, Bajaj Finance is categorized as very expensive with a PE ratio of 33.5, while Life Insurance is rated very attractive with a PE of 11.39.
In comparison to its peers, Symbiox Investme's ratios suggest a strong valuation proposition, especially when considering its EV to EBITDA of -2.51, which highlights its current undervaluation relative to the market. Despite recent stock performance showing a decline of 49.26% year-to-date compared to a 3.29% increase in the Sensex, the company's attractive valuation metrics suggest potential for recovery and growth in the future.